Aldeyra将获得100万美元的不可退还的期权费,如果艾伯维选择行使期权,...查看全文
冷小二2023-11-01 22:41
$Aldeyra Therapeutics(ALDX)$ 与$艾伯维公司(ABBV)$ 就前者的干眼病候选药物 reproxalap 签署了独家选择权协议。
根据协议,艾伯维可以选择在美国获得共同独家许可,并在美国境外获得独家许可,以开发、制造和商业化该药物。
Aldeyra 将获得 100 万美元的期权费。 如果艾伯维选择行使该选...查看全文
产业链观察2023-11-01 21:35
#药闻简讯# 2023 年 11 月 01 日--致力于发现和开发治疗免疫介导疾病的创新疗法的生物技术公司$Aldeyra Therapeutics(ALDX)$ 今天宣布,公司已与艾伯维公司达成独家期权协议。
根据期权协议的条款,艾伯维有权获得在美国开发、制造和商业化reproxalap的共同独家许可,以及在美国以外开发、制造...查看全文
chuminhua2023-10-17 11:27
10/16,Aldeyra Therapeutics $Aldeyra Therapeutics(ALDX)$ 表示, FDA 发现该公司干眼病药物reproxalap 的上市申请存在“实质性审查问题”,周一该公司股价暴跌 67%。 今年早些时候,美国监管机构已接受这款用于治疗干眼病体征和症状的眼部局部药物的上市申请,并设定了 11 月 23 日作为做出决定...查看全文
智通财经APP获悉,2月7日,Aldeyra Therapeutics(ALDX.US)宣布FDA已接受其在研眼药水Reproxalap治疗干眼症的新药申请。FDA预计在2023年11月23日前完成审查。据悉,Reproxalap是一种潜在首创小分子促炎性活性醛类物质(RASP)抑制剂,能降... 网页链接
$Aldeyra Therapeutics(ALDX)$ 美东时间 2016-03-30 09:00 Before Open:ALDEYRA THERAPT Earning Release . Wall St EPS Est ($):-0.30. 网页链接
$Aldeyra Therapeutics(ALDX)$ 8-K - Current report Filed: 2016-03-18 AccNo: 0001193125-16-510480 Size: 74 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain OfficersItem 9.01: Fi...
$Aldeyra Therapeutics(ALDX)$ 8-K - Current report Filed: 2016-03-09 AccNo: 0001193125-16-497552 Size: 9 MBItem 1.01: Entry into a Material Definitive AgreementItem 7.01: Regulation FD DisclosureItem 9.01: Financial Statements and Exhibits 网页链接
$Aldeyra Therapeutics(ALDX)$ 8-K - Current report Filed: 2016-02-29 AccNo: 0001193125-16-483534 Size: 35 KBItem 7.01: Regulation FD DisclosureItem 8.01: Other EventsItem 9.01: Financial Statements and Exhibits 网页链接
$Aldeyra Therapeutics(ALDX)$ SC 13G - Statement of acquisition of beneficial ownership by individuals Filed: 2016-02-16 AccNo: 0001019056-16-001112 Size: 96 KB 网页链接
$Aldeyra Therapeutics(ALDX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2016-02-16 AccNo: 0001193805-16-002581 Size: 316 KB 网页链接
$Aldeyra Therapeutics(ALDX)$ SC 13G/A [Amend] - Statement of acquisition of beneficial ownership by individuals Filed: 2016-02-12 AccNo: 0000315066-16-004830 Size: 9 KB 网页链接
$Aldeyra Therapeutics(ALDX)$ 8-K - Current report Filed: 2016-02-02 AccNo: 0001193125-16-447637 Size: 14 KBItem 5.02: Departure of Directors or Certain Officers; Election of Directors; Appointment of Certain Officers: Compensatory Arrangements of Certain Officers 网页链接
$Aldeyra Therapeutics(ALDX)$ 8-K - Current report Filed: 2016-01-11 AccNo: 0001193125-16-425698 Size: 12 KBItem 7.01: Regulation FD Disclosure 网页链接
$Aldeyra Therapeutics(ALDX)$ 8-K - Current report Filed: 2015-12-01 AccNo: 0001193125-15-391292 Size: 12 KBItem 7.01: Regulation FD Disclosure 网页链接